Cobimetinib and trametinib inhibit platelet MEK but do not cause platelet dysfunction

The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone. Platelets express several members of the MAPK signalling cascade including MEK1 and MEK2 and ERK1 and ERK2 but t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Platelets
Päätekijät: Unsworth, Amanda J., Bye, Alexander P., Kriek, Neline, Sage, Tanya, Osborne, Ashley A., Donaghy, Dillon, Gibbins, Jonathan M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Taylor & Francis 2018
Aiheet:
Original Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6594423/
https://ncbi.nlm.nih.gov/pubmed/30252580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/09537104.2018.1514107
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia